Clinical Trials

The purpose of this study is to test whether an over-the-counter ketone ester drink is well tolerated in people with heart failure on, and not on, a heart failure medication class called SGLT2 inhibitors. The research team is trying to determine the safest dose of Delta G.

HeartShare is a comprehensive study of heart failure, a common and serious medical condition which occurs when the heart is unable to keep up with the demands of the body, resulting in shortness of breath, fluid retention, and fatigue. HeartShare aims to better classify heart failure into subtypes to help develop more personalized treatments for patients, with the hope that this will improve the lives of heart failure patients. To do this, HeartShare is bringing together a large amount of data (including images, such as heart ultrasounds and MRIs and molecular data from the blood, such as genetics) from previously conducted studies and electronic health records, and is gathering new data through participants enrolled in the HeartShare Deep Phenotyping Study.

Do you want to help find new treatments for heart failure with preserved ejection fraction? This study is testing whether a medicine called spironolactone can help treat heart failure with preserved ejection fraction when paired with the standard treatment. Spironolactone helps to remove excess water and sodium from the body. To participate in this study, you must be between 50 and 99 years old and diagnosed with heart failure with preserved ejection fraction.

Are you an adult with ischemic or non-ischemic cardiomyopathy? This observational study will group and follow patients at a higher risk for sudden cardiac death (SCD) who receive an implantable cardioverter defibrillator (ICD) pulse generator replacement as a prevention measure. The study hypothesizes that abnormalities of the heart, some of which are genetically determined, can be used to identify patients at high risk of SCD. To participate in this study, you must be between 18 and 85 years old and have ischemic or non-ischemic cardiomyopathy. You must also be getting your initial ICD implant for primary prevention or a programmed generator replacement if the ICD was originally implanted for SCD primary prevention. The study takes place in Baltimore, Maryland; Richmond, Virginia; and Washington, DC.

Do you have heart failure with preserved ejection fraction (HFPEF)? This study is testing the efficacy of a diuretic medicine called spironolactone that stops your body from absorbing too much salt and keeps your potassium levels from dropping too low. Participants of this study must be between 50 and 99 years old and already taking diuretic medicine. This study takes place in multiple locations across the United States and Sweden.